A Phase 3 interventional study of suprachoroidal CLS-TA and suprachoroidal sham in Macular Edema and Retinal Vein Occlusion, sponsored by Clearside Biomedical, Inc.. Terminated at 110 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.
Sponsored by Clearside Biomedical, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing Triamcinolone Acetonide in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone Acetonide · Macular Edema.
Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, this one is the 4th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 3, and was the 18th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 26 studies testing Triamcinolone Acetonide in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Healthy volunteers
By country, each count listing its studies:
Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 10 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 460 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 75 across the 25 interventional studies. Of the 22 that completed or were terminated, 5 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 26 have an industry lead sponsor. The 10 most frequent:
Clearside Biomedical, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Clearside Biomedical, Inc. has 5 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
Drug: suprachoroidal CLS-TA · Drug: IVT aflibercept
IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
Drug: suprachoroidal sham · Drug: IVT aflibercept
suprachoroidal injection of CLS-TA
Also known as: Triamcinolone acetonide
suprachoroidal sham procedure
2 mg intravitreal injection of aflibercept
Also known as: Aflibercept
Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)
Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.
Time frame: 2 months
Mean Change From Baseline in Best Corrected Visual Acuity
Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.
Time frame: 6 months
Mean Change From Baseline in Central Subfield Thickness
Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.
Time frame: 6 months
| Milestone | Active | Control |
|---|---|---|
| Started | 231 | 229 |
| Completed | 128 | 127 |
| Not completed | 103 | 102 |
| Withdrew: Adverse event | 2 | 7 |
| Withdrew: Withdrawal by subject | 7 | 2 |
| Withdrew: Lost to follow-up | 5 | 5 |
| Withdrew: Includes premature discontinuation due to study termination. | 88 | 88 |
| Withdrew: Unknown study completion status | 1 | 0 |
Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.
| Participants | Active | Control |
|---|---|---|
| Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) | 114 | 127 |
Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.
| Letters | Active | Control |
|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity | 15.5 ± 0.85 | 20.5 ± 0.85 |
Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.
| Microns | Active | Control |
|---|---|---|
| Mean Change From Baseline in Central Subfield Thickness | -354.3 ± 8.01 | -416.2 ± 8.05 |
Collected over Adverse events were collected over 48 weeks of follow-up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active | 0/231 (0%) | 25/231 (10.8%) | 128/231 (55.4%) |
| Control | 0/229 (0%) | 28/229 (12.2%) | 83/229 (36.2%) |
| Event | Active | Control |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/231 | 3/229 |
| Transient ischaemic attackNervous system disorders | 0/231 | 3/229 |
| Intraocular pressure increasedInvestigations | 3/231 | 0/229 |
| Coronary artery diseaseCardiac disorders | 0/231 | 2/229 |
| Myocardial infarctionCardiac disorders | 0/231 | 2/229 |
| Chest painGeneral disorders | 1/231 | 2/229 |
| Atrial fibrillationCardiac disorders | 2/231 | 1/229 |
| Visual acuity reducedEye disorders | 2/231 | 0/229 |
| Urinary tract infectionInfections and infestations | 2/231 | 0/229 |
| HyponatraemiaMetabolism and nutrition disorders | 2/231 | 0/229 |
| Event | Active | Control |
|---|---|---|
| Conjunctival haemorrhageEye disorders | 42/231 | 28/229 |
| Intraocular pressure increasedInvestigations | 33/231 | 9/229 |
| CataractEye disorders | 21/231 | 9/229 |
| Cataract subcapsularEye disorders | 20/231 | 3/229 |
| Eye painEye disorders | 20/231 | 11/229 |
| Visual acuity reducedEye disorders | 16/231 | 6/229 |
| HypertensionVascular disorders | 15/231 | 15/229 |
| Macular oedemaEye disorders | 8/231 | 13/229 |
| NasopharyngitisInfections and infestations | 9/231 | 13/229 |
| Vitreous detachmentEye disorders | 13/231 | 9/229 |
The Safety population included all randomly assigned subjects who were administered at least one dose of the study drug.
| Age, Categorical(Participants) | Active | Control | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 89 | 107 | 196 |
| >=65 years | 142 | 122 | 264 |
| Age, Continuous(Years) | Active | Control | Total |
|---|---|---|---|
| Mean | 66.4 ± 12.31 | 64.9 ± 12.42 | 65.7 ± 12.37 |
| Sex: Female, Male(Participants) | Active | Control | Total |
|---|---|---|---|
| Female | 97 | 105 | 202 |
| Male | 134 | 124 | 258 |
| Race (NIH/OMB)(Participants) | Active | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 33 | 40 | 73 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 10 | 12 | 22 |
| White | 181 | 177 | 358 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Region of Enrollment(Participants) | Active | Control | Total |
|---|---|---|---|
| Hungary | 6 | 1 | 7 |
| United States | 182 | 183 | 365 |
| Philippines | 0 | 3 | 3 |
| United Kingdom | 4 | 2 | 6 |
| Portugal | 3 | 2 | 5 |
| India | 13 | 19 | 32 |
| Spain | 3 | 2 | 5 |
| Canada | 2 | 3 | 5 |
| Taiwan | 2 | 1 | 3 |
| Denmark | 2 | 1 | 3 |
| Poland | 5 | 5 | 10 |
| Slovakia | 0 | 1 | 1 |
| Australia | 9 | 6 | 15 |
| Type of Retinal Vein Occlusion(Participants) | Active | Control | Total |
|---|---|---|---|
| Branch retinal vein occlusion | 124 | 124 | 248 |
| Central retinal vein occlusion | 107 | 105 | 212 |
Showing the first 100 of 110 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Dec 2018, 22 months.
Results were first posted in Apr 2021, 2 years 4 months after primary completion. A results delay was requested in Dec 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide
Clearside Biomedical, Inc.